ImmuneBiotech Medical Sweden AB, the probiotic and microbiome company, is pleased to announce the market launch of its first product – GutMagnific™ as a food supplement for gut- related conditions on the company’s web shop www.GutMagnific.com.
GutMagnific™ is a super-consortium (combination) of five probiotic lactobacillus strains, scientifically designed to address the underlying key causes of IBS and will be sold as a food supplement supported by clinical data. GutMagnific™ is the first product in a new probiotic category ImmuneBiotics™ where products are developed using pharmaceutical precision focused on achieving a healthy balance between the microbiome, the immune system, and the intestinal barrier.
“I’m extremely pleased that our more than 15 years of experience in probiotics, immunology, microbiology and research in the gut-brain-axis has matured to a probiotic supplement ready for the market. There are many probiotic products out there, most of these do not have an effect on chronic conditions. To me, customer needs have always been the main motivation and we have designed GutMagnific™ based on input from physicians and customers using similar research methods as in drug development. We are proud of our highly innovative probiotic supplement that can help many people with years of suffering from gut-related conditions.” said Shahram Lavasani, CEO of ImmuneBiotech.
About ImmuneBiotech Medical AB:
ImmuneBiotech discovers and markets science-based probiotic food supplements. Based on our multi-disciplinary scientific foundation, we deliver innovative probiotic products scientifically designed to modulate the gut microbiota, reduce gut permeability and reduce inflammation.
GutMagnificTM is a super-consortium of five probiotic strains scientifically designed to address the underlying key causes of IBS. It is a patent pending combination of proprietary lactobacillus strains and will be sold as a food supplement supported by clinical data. GutMagnificTM has potential application in several severe and prevalent conditions such as IBS, diarrhea, antibiotic induced diarrhea, Clostridium difficile infection (CDI) and Chronic Fatigue Syndrome (ME/CFS). Is has also the ability to target symptoms such as leaky gut and small intestine bacterial overgrowth (SIBO).
ImmuneBiotech AB, Medicon Village, SE-223 81 Lund, Sweden Visitor address: Scheelevägen 2 www.immunebiotech.com
ImmuneBiotech is an alumni to SmiLe Incubator